Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

LambdaTest rallies global investors raising US$16m Series B funding as it rapidly scales

Stockwood Strategy

Cloud-based browser testing platform LambdaTest today announced it has secured US$16 million in Series B funding led by Sequoia Capital India. Telstra Ventures, MENA region investor Wamda Capital and a leading sovereign wealth fund also joined the series B round. Founded in 2017 by Asad Khan and Jay Singh, San Francisco-based LambdaTest is a cloud-based testing infrastructure company that allows users to seamlessly test their websites’ and apps’ look, feel and performance on over 2,000 different browsers and by operating systems and device combinations. The proliferation of devices and browsers has made it increasingly complex for developers to test their websites and apps. LambdaTest solves this problem by enabling developers to run a variety of tests through their cloud-based platform, spotlight concerns, share immediately with teams and remedy issues quickly. LambdaTest exists to support the developer community to identify defects in code much earlier in the release cycle. These defects present one of the biggest challenges and costs facing businesses. Indeed, the cost of fixing these defects once in production and release is 30x higher than addressing earlier in the development cycle. Since its launch, LambdaTest has attracted over 500,000 developers in 132 countries who have performed more than 20 million tests. Customers include SMEs and Fortune 500 companies such as Xerox, Cisco, Microsoft, Deloitte, Media.net, Coca Cola, Trepp, SurveyMonkey, Capgemini, HBR, 23andme and Dashlane. Asad Khan, CEO of LambdaTest commented: “Companies are increasingly competing on customer experience 1 and as such are releasing software updates faster, more frequently to remain relevant. In doing so, there is a greater demand for continuous testing to ensure quality releases in the production environment. In just six short months since the series A round in 2020, LambdaTest has doubled revenues and increased customer numbers by 20%. In that time headcount has doubled in size from 70 people pre-Series A to 150 today across the engineering, sales, and customer success teams. Harshjit Sethi, Principal at Sequoia India commented: “As every company is becoming a software company and deployment cycles are shrinking, testing is becoming an increasingly important part of the software development cycle. Additionally testing is now happening earlier and earlier in the development cycle as part of the ‘Shift Left’ movement that companies like LambdaTest are enabling. Operating in a USD 35 billion market for testing software and services, LambdaTest has emerged as the go-to platform for its users in browser testing, evident from its best-in-class ratings across review sites. Sequoia Capital India is excited to continue partnering with the LambdaTest team as they execute on their vision of building an end-to-end testing system for developers to enable companies to release more reliable software faster.” The number of software tests run by developers has almost doubled from 12m to over 20m in six months at LambdaTest. As developers shift to cloud-based testing, this number will grow exponentially. This trend has been accelerated by the adoption of the Shift Left approach, as more developers are testing code early before they ship to the testing cycles. “LambdaTest’s vision is to empower 23 million developers and testers worldwide with a powerful, comprehensive and secure continuous quality test platform. Our upcoming product lines will enable tech teams to ship high quality code seamlessly boosting their release velocity” added Asad Khan. Steve Schmidt, General Partner at Telstra Ventures commented: “We have an opportunity to build a very large scale and independent testing company with a modern approach to software development and that’s very exciting. Lambdatest has already signed several customers in Australia without having any local presence and we look forward to helping them build out a local APAC team to meet this demand”. The funding advances LambdaTest’s commitment to scaling the testing ecosystem and building next-generation cloud infrastructure for users. To this end, LambdaTest is broadening its reach with the tester community by engaging with developers as it launches a suite of products in 2021 designed for them to perform tests on scale. “We’ve had an exciting period of growth and there is more to come as we expand our platform capabilities and go deeper in global markets. This funding round validates our efforts in building a robust cloud testing platform that is truly resonating with the testing and developer community globally. We pride ourselves in delivering a highly reliable, stable and secure infrastructure for them to achieve success. This success is born out in the numbers as our customers have been able to increase release velocity by over 60% and half the time to market” concluded Asad Khan. About LambdaTest LambdaTest is a cloud testing infrastructure company that allows users to run both manual and automated tests on their websites and webapps across 2000+ different browsers, browser versions and operating system environments. The platform has been used to perform over 20 million tests in just three years, and is now being used by over 500,000 users across 132 different countries. Contact Details LambdaTest Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.theeditldn.com/

June 02, 2021 05:00 AM Eastern Daylight Time

Image

American Kidney Fund Receives Support from Bayer to Expand Kidney Disease Education Among U.S. Veterans

American Kidney Fund

The American Kidney Fund (AKF) today announced support from Bayer for AKF’s effort to educate military veterans about the central role their kidneys play in their overall health and the importance of early detection to prevent or slow the progression of kidney disease. Bayer’s collaboration supports AKF’s existing partnership with the U.S. Department of Veterans Affairs (VA) Veterans Health Administration to increase awareness of kidney disease among U.S. veterans and to support veterans who have been diagnosed with kidney disease. “About 500,000 U.S. veterans have kidney disease, and that number continues to trend upward by 6% each year, as it has for the past five years,” said LaVarne A. Burton, AKF president and CEO. “We are grateful for Bayer’s support of our work to reach out to veterans—a population that faces higher rates of kidney disease compared to the general public.” "A major risk factor for chronic kidney disease is type 2 diabetes and many veterans living with type 2 diabetes do not realize they are at risk," said Amit Sharma, M.D., FACP, FASN, FNKF, Vice President of Medical Affairs, Cardiovascular & Renal Division, Bayer. “Bayer is proud to support AKF’s work to educate America’s veterans on kidney disease risk factors, early detection and disease management, to help all veterans living with kidney disease live healthier lives.” Kidney disease is the fastest growing noncommunicable disease in the U.S., yet 90% of Americans, including veterans, with the early stages of kidney disease are unaware they have it because there are typically no symptoms until the later stages. Diabetes and hypertension cause 75% of all new cases of kidney disease. About the American Kidney Fund The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar. For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn. 11921 Rockville Pike, Suite 300, Rockville, MD 20852 Contact Details Ben Shannon Work: +1 202-559-2813 Mobile: +19193603039 AKF@jpa.com Company Website https://www.kidneyfund.org

May 27, 2021 09:00 AM Eastern Daylight Time

British online store The Edit LDN transforms prized sneaker industry as sales soar

Stockwood Strategy

The UK’s leading online store for limited edition sneakers and high end streetwear The Edit Man London has become The Edit LDN. The name change reflects the rapidly growing female appeal for new and pre-loved sneakers and streetwear as sales grow 60% month-on-month in the last 12 months. The Edit LDN is an online consignment store that sells new and pre-loved goods from a variety of brands including Yeezy, Jordan, Louis Vuitton, Dior, Off-White, Supreme, Fear of God among others to a wide community of fashionistas, collectors and investors. Just as premium sites like Farfetch address the fashion world, The Edit LDN is the leading destination for limited edition sneakers and high end streetwear. They connect premium resellers with a highly engaged, price agnostic and eager audience. Through partnerships with styling services such as Thread.com and various concierge companies, THE EDIT LDN has expanded its community of buyers from TV and film celebrities to professional footballers and royal families around the world. Moses Rashid, founder and CEO of The Edit LDN commented: “As a brand we want to remain current and relevant to our community, our new name now fairly represents and embraces our diverse community but is true to its origins. We dropped the ‘Man’ from the name simply because the number of women buying had been steadily increasing since launch in January 2020 and passed 50% in March this year. It was the right thing to do.” The Edit LDN has established itself as a trusted source of authenticated and high quality new and pre-loved streetwear and sneakers. Their unabating focus on speed (to deliver purchased goods), customer service engagement and ensuring all goods are authenticated has been testament to the growth of the platform and community. “We set out to create a destination that opens up and levels up the opportunity for anyone wishing to own extremely limited edition goods. Essentially we make Inaccessible, accessible. Previous means to buy these goods have been riddled with issues such as sending payments to random resellers found on social media, authenticity issues when buying online and long delivery times on purchases from global marketplaces. The Edit LDN addresses all these concerns and is transforming the customer experience and industry simultaneously, added Moses ”. In 2021 (to April), The Edit LDN attracted more traffic, transactions and revenue than in their first year of trading (2020). With 60% month-on-month growth and mounting interest, the business is set to take-off. “We’re regularly selling sneakers and streetwear worth £1,500 each. Recently, we sold a Gucci TNF jacket for £9,200. It’s not only the variety of goods we offer but the speed at which we send purchases. Just last year we managed to source and sell 44 Playstation 5 games consoles to the England U21 football team within 24 hours, literally dispatching them in Ubers to their homes” said Moses. Looking ahead, Moses added: “This is a marketplace worth $6b a year globally and will grow 5x by 2030. By the end of this year, The Edit LDN will be worth £10m and given the hyper growth rate of our sales and revenues, we will 3x our valuation by the end of 2022 for sure. In meeting the needs of this rapid scaling, we will seek to raise funds this year to propel us as we launch in new markets”. The Edit LDN has its community and social conscious front of mind. They have raised funds and awareness against gun crime, mental health and sustainability issues. In 2020, the company collaborated with the artist McCrow as part of the One Less Gun campaign to create a sneaker with bullet shells from an AK-47 rifle. Working with Gary James McQueen in aid of MIND mental health charity, they raised funds with an exclusive T-shirt drop featuring the famous McQueen Vanitas skull. In owning their sustainability agenda, they turned their focus to the circular economy by selling pre-owned (or pre-loved) goods through the platform. In addition to this, they are a paperless company and only ship products using recycled packaging. “At the heart of The Edit LDN proposition is a focus on social and economic issues. These are matters that are important to us and our community, so we recognise that we’re in a super hot market right now so we want to use our platform to make a long lasting impact where possible” concluded Moses. About The Edit LDN Founded in 2020, The Edit LDN has quickly become the UK’s leading online consignment store for limited edition sneakers and high end streetwear, both new and pre-loved items. Their innovative platform connects premium resellers to a global audience offering a deluxe experience from discovery, packaging and delivery. Brands include Jordan, Yeezy, Louis Vuitton, Dior, Off-White, Supreme, Fear of God among others. The platform is fast becoming synonymous with speed of service, authenticity, diverse selection of secure payment methods, and first class customer service. The Edit LDN is the leading destination for resellers and their premium sneakers and streetwear. Through partnerships with styling services such as Thread.com and various concierge companies, The Edit LDN has a community of buyers celebrities to professional footballers and royal families around the world. Contact Details The Edit LDN Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://www.theeditldn.com/

May 27, 2021 05:00 AM Eastern Daylight Time

Image

Elsevier Supports the State of California in Expanding COVID-19 Online Learning Program for Registered Nurses

Elsevier

In response to the increased need for skilled healthcare workers during the pandemic, many hospitals in California are calling upon adjunct nursing staff that don’t typically work in the ICU to offer additional support in the care of critically ill patients Elsevier, a global leader in research publishing and information analytics, announced today that it is working with the State of California Emergency Medical Services (EMS) Authority and the American Association of Critical-Care Nurses (AACN) to expand its COVID-19 online training for adjunct nursing staff who can provide additional support in the intensive care units (ICU) during the pandemic. The week-long online curriculum, created by the AACN, is designed to help adjunct nursing staff who don’t typically work in the ICU to enhance their clinical skills and knowledge on caring for patients with the novel coronavirus, SARS-CoV-2. Registered nurses in California can learn more about this continuing education training option and how to register by visiting the EMS Authority’s website. John Danaher, MD, President, Clinical Solutions, Elsevier, said: “We are continuing to work with the State of California to support frontline workers who are playing such an important role in our local communities. Hundreds of newly trained nurses in California have completed the initial training program and are providing additional support in ICUs across the state. We look forward to our continued collaboration and doing everything we can to support patient care.” Some of the learning modules included in the expanded program include Critical Care Patient Management, Acute Coronary Syndrome (ACS), Assessing and Managing Respiratory Failure, and Managing Oxygenation and Ventilation. Elsevier is committed to supporting clinicians and students and helping them improve outcomes. In April 2020, Elsevier launched its COVID-19 Healthcare Hub, which provides free access to toolkits, expert insights, research resources and COVID-19 guidelines. The Hub’s resources include evidence-based clinical overviews, drug monographs, care plans, order sets, and procedure videos for clinicians delivering care and information to patients. Clinicians will also find the latest information and guidelines from government health agencies, medical societies and public health organizations for diagnosis, testing and treatment of COVID-19 patients. To help address the wave of misinformation about the virus and support clinicians in India, Elsevier recently launched the India Covid-19 Healthcare Hub. The website includes short synoptic clinical overviews, medication information, and easy-to-understand videos and instructions for patients. Additionally, AACN hosts a COVID-19 Resources page on its association site that provides free access to clinical and supportive resources ensuring nurses have the information and support to best care for their patients and themselves throughout the pandemic. About the American Association of Critical-Care Nurses For more than 50 years, the American Association of Critical-Care Nurses (AACN) has been dedicated to acute and critical care nursing excellence. The organization’s vision is to create a healthcare system driven by the needs of patients and their families in which acute and critical care nurses make their optimal contribution. AACN is the world’s largest specialty nursing organization, with more than 130,000 members and over 200 chapters in the United States. American Association of Critical-Care Nurses, 27071 Aliso Creek Road, Aliso Viejo, CA 92656; 949-362-2000; www.aacn.org; facebook.com/aacnface; twitter.com/aacnme About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Contact Details American Association of Critical-Care Nurses – Communications Kristie Aylett kristie.aylett@aacn.org Elsevier Communications – Vice President, Global Health Markets Teresa Mueller +31620987384 t.mueller@elsevier.com

May 26, 2021 01:45 PM Pacific Daylight Time

Is it Possible to Kill Corona Virus from Luggage Surfaces in Just 5 Seconds? University Study Says "Yes"

WarpUV

Following extensive testing, the Microbial Pathogenesis Laboratory at Tel Aviv University has concluded the WarpUV ® AirFort® luggage disinfection system can eradicate coronaviruses in just five seconds. For airports, baggage handlers and air passengers, the study findings show air travel can be safer again because luggage surface areas that typically pass through many hands on their way to, from and at the airport, and susceptible to airborne transmissible droplets, can be safely and quickly sanitized. Prof. Anat Herskovits, a world-renowned microbiologist, Vice Chair of the Shmunis School of Biomedicine and Cancer Research, and President of the Israel Society of Microbiology, tested the ability of the WarpUV AirFort® technology to kill high concentrations of coronaviruses. “Our results concluded that after five seconds of UV irradiation, more than 99 percent of the viruses were eradicated,” Prof. Herskovits said. “I feel confident that WarpUV has developed an effective solution for luggage disinfection.” Resources: Hear audio quote from Prof. Herskovits (.wav,.mp3) Post-COVID-19 Air Travel/Bio-Security survey, May 2021 Breakthrough Rapid-Action Coronavirus and Bacteria Disinfection Technology for Passenger Luggage at Airports Stops Local Outbreaks from Becoming Global Pandemics AirFort® is designed to rapidly kill viruses, bacteria, and spores from surface contamination of carry-on and checked bags, personal items and oversized bags and parcels, protecting baggage handlers, aviation staff, and the general public. It utilizes a proprietary array of ultraviolet lights designed to achieve all-angle “360° x 360°” disinfection of all baggage surfaces. While floor UV cleaners and other disinfection agents such as sprays are being implemented globally, AirFort focuses on luggage – one of the means that the International Air Transport Association (IATA), European Union Aviation Air Safety Agency (EASA), and the U.S. Department of Homeland Security identified as a possible critical path for viruses and bacteria to infect and spread. By eradicating these harmful elements before and after flights, WarpUV has an important role in stopping the spread and future spread of pandemics which are imminent threats as described by the EU, WHO, and the World Economic Forum. About WarpUV Warp Technologies and its AirFort® devices are the frontline of prevention of the spread of pandemic by luggage and baggage in airports worldwide and serve as a “disinfection firewall” for continents, countries, and regions. The company was formed in 2020 by veteran Israeli entrepreneurs Amir Fischer, Eitan Haimovich, and Gil Luxenbourg. For more information, visit www.warpUV.com. Contact Details Rainier Communications Alan Ryan +1 508-577-6635 alanryan@rainierco.com Rainier Communications Joanne Stanway +19782731473 jstanway@rainierco.com Company Website https://www.warpuv.com/

May 26, 2021 02:30 PM Eastern Daylight Time

Dogs Don’t Know, Heat Can Hurt: How to Recognize the Warning Signs of Exercise-Induced, Heat Related Illness

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/Q9_KZTWQXCU It’s summer, and everyone wants to be outside with their dogs. But it’s hot, and when our best friends are chasing frisbees, balls, and running they don’t always know they’re overheating. If their core body temperatures rise faster than they can cool off, dogs may suffer from Heat Related Illness (HRI). National Heat Awareness Day is May 28, 2021, and EUKANUBA™ wants you to learn how to keep your dog safe while exercising this summer. EUKANUBA™, a premium dog food brand specializing in high-performance nutrition for sporting and working dogs, is drawing attention to canine exercise-induced heat related illness (HRI) by conducting a nationwide media tour in conjunction with D S Simon Media and Your Update TV featuring Dr. Joe Spoo, Veterinarian, Eukanuba™. During the nationwide media tour and Public Service Announcement (PSA) Dr. Spoo discussed: What is a Heat Related Illness The Three Stages: Heat Stress, Heat Exhaustion, and Heat Stroke. How to recognize the HRI warning signs in your dog. How dogs naturally cool down. What type of dogs are at risk. Ways to keep them cool while exercising and having fun. The importance of hydration For more information please visit: EUKANUBA.com About YourUpdateTV: YourUpdateTV is a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

May 26, 2021 12:00 PM Eastern Daylight Time

Video

Dr Hen launches STI Education Series, Exclusively on Social Media

Dr Hen

Dr Hen, the popular social media Hen doctor, has launched a content series highlighting digestible STI education and prevention, as the U.S. predicts a record surge in STI rates this summer. The content series comes hot off the heels of vaccine roll-outs - with 50% of Americans now being vaccinated, singles are gearing up for a hot summer and Dr Hen is aiming to destigmatize STI awareness with its educational series. The ‘ Dr Hen Says’ STI series launches May 25, with content posted throughout the summer until July 15. The series will present multiple illustrated panels, with the goal of modernizing and simplifying health education, ultimately, putting people’s health information in their own hands. Additionally, the series will cover leading diseases and concerns, including; herpes, gonorrhea, HPV facts, curable and incurable STIs, risk factors, and simple treatment measures. “I created a social platform as I saw the need for a safe space dedicated to sharing and building a community where individuals can help each other stay informed on leading health topics - something we need now more than ever,” said Dr Hen, Chief Physician of the Medical Center in Hen World. “We are beginning to experience a post-pandemic world, with STIs being one of many health concerns to surface - the platform aims to address these topics in a non-judgemental and compassionate way.” As Covid restrictions across the nation continue to ease, the pent up (sexual) frustration is real. The CDC notes that those aged between 15-24 years of age are amongst the most popular age group to experience leading STIs, including chlamydia and gonorrhea. Coupled with this being the same age group to retrieve the majority of their information from social media, we have a generation that is in need of quick, easy, and accurate information directly from their phone - and Dr Hen is the answer. With 72% of the United States population active across social media, online health education has seen a steady increase due to its ability to remove physical barriers that traditionally impede access to healthcare support and resources. As selected health topics, including STIs, mental health, and AIDS, continue to be stigmatized, the need for an inclusive and approachable online platform with accurate information has never been more important. With a rapidly growing Instagram page of 148K followers, the testimonials speak for themselves as Dr Hen Says has become a popular and go-to health platform for many in the U.S. and across the globe. The platform destigmatizes the world of health, ultimately breaking through negative and inaccurate health concerns, offering individuals around the world the opportunity to overcome any barriers to accessing quality health information through modern devices. ABOUT DR HEN SAYS: Dr Hen is a Chief Resident, writer and illustrator in the animated planet called Hen World. This Instagram influencer is renowned for encouraging awareness, dialogue, and building communities around difficult health topics. With so much misinformation and toxicity on social media, Dr Hen is there to break through the negativity with a voice of compassion, empathy, inclusiveness, decency and diversity. Dr Hen believes in empowering readers to actively seek and share knowledge in order to gain greater control over decisions relating to their own health. Aiming to establish a destigmatized world of health, Dr Hen is making health more approachable by raising awareness and fighting misinformation. Instagram: @drhensays YouTube: Dr Hen Says Twitter: @drhensays Facebook: @drhensays *Statistics included from ‘CDC Newsroom’, Reported STDs Reach All-time High for 6th Consecutive Year; ‘Statista’, Reach of leading social networking sites used by teenage and young adult online users in the United States as of 3rd quarter 2020; ‘Statista’, Active social network penetration in selected countries as of January 2021; The New York Times’ interactive COVID-19 vaccine tracker: Tracking Coronavirus Vaccinations Around the World by Josh Holder. Contact Details Jive PR + Digital Lynsey Gray +1 250-505-6434 lgray@jiveprdigital.com Company Website https://hen.world/

May 26, 2021 11:33 AM Eastern Daylight Time

Image

American Kidney Fund Applauds Texas for Enacting Protections for Living Organ Donors

American Kidney Fund

The American Kidney Fund (AKF) commends Texas Governor Greg Abbott for signing into law important protections for living organ donors. H.B. 317 prohibits life, disability and long-term care insurers from discriminating against living organ donors by declining or limiting coverage due to their status as an organ donor, charging living organ donors more for a policy, and from precluding a person from donating all or part of an organ as a condition of their policy. AKF worked closely with bipartisan H.B. 317 sponsors Rep. Andrew Murr in the House and Sen. Boris L. Miles—a kidney transplant recipient himself—in the Senate to move the bill through the Texas Legislature. AKF is spearheading the nationwide effort to pass living donor protections at the state level, and since 2019, 16 states have signed these bills into law, including New Jersey, Washington, Pennsylvania and Kentucky earlier this year. “The American Kidney Fund applauds Texas for enacting legislation that will ensure no one who chooses to make the lifesaving gift of organ donation falls victim to discriminatory insurance practices because of that decision,” said LaVarne A. Burton, AKF president and CEO. “Governor Abbott’s signature on this bill will remove barriers for living organ donors and ultimately will save lives by increasing the number of kidneys and other organs available for Texans who are awaiting transplantation.” Increasing living donor protections is a cornerstone of AKF’s policy agenda, and earlier this year, AKF released its first annual State of the States: Living Donor Protection Report Card, which measures seven types of legislation states should enact to provide protections for living organ donors and encourage living donations. In the absence of federal legislation to protect living donors, there is an uneven patchwork of protections across the nation, with some states providing no protections at all. H.B. 317 is Texas’ second piece of living donor legislation, moving the state’s Report Card grade up from a D to a C. “Even as we recognize the significance of Texas’ enactment of this legislation, we recognize that there is much more that needs to be done nationwide to secure living donor protections,” said Burton. At the federal level, AKF continues to advocate for the Living Donor Protection Act of 2021 (H.R.1255/S.377), which would ensure a uniform baseline of living donor protections nationwide. Most transplanted organs are from deceased donors, but patients may also receive organs from living donors. Living donation offers an alternative for individuals awaiting transplantation from a deceased donor and increases the existing organ supply. Transplants from living donors generally have fewer complications than deceased-donor transplants and a longer survival of the donor organ. There are more than 107,000 Americans on the organ transplant waiting list and nearly 93,000 of them, or 86%, are waiting for a kidney. More than 8,300 Texans are on the kidney transplant waiting list. Of the 23,644 kidney transplants performed in the U.S. in 2020, just 5,234 were made possible by living organ donors. In Texas, 613 of 2,242 kidney transplants were from living donors. AKF provides long-term financial assistance that makes transplants and post-transplant care possible for low-income dialysis patients. In 2020, AKF grants helped 1,615 people nationwide receive kidney transplants—7% of all kidney transplants performed in the United States last year. AKF’s program helps post-transplant patients for their full insurance plan year, ensuring continuity of care. About the American Kidney Fund The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation’s leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease—from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation’s top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar. For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn. Contact Details Ben Shannon Work: +1 202-559-2813 Mobile: +19193603039 AKF@jpa.com Company Website http://www.kidneyfund.org/

May 25, 2021 11:00 AM Eastern Daylight Time

Discover AEGIS VES 240® – the latest addition to the AEGIS System of Care™

AEGIS Environmental Management Inc.

AEGIS Environmental Management Inc. has announced the launch of the AEGIS VES 240 ® commercial cleaner-disinfectant, an innovative two-in-one product that simultaneously cleans and sanitizes in just 15 seconds. This new addition to the AEGIS range offers effective disinfection for a broad range of hard, non-food contact surfaces – as well as acting as a sanitizer for fabrics – helping to maintain cleaner treated surfaces in offices, retail, restaurants, hospitals, schools and industrial settings. AEGIS VES 240 is a one-step, US EPA-registered commercial cleaner-disinfectant that is effective against odor-causing and pathogenic bacteria, fungi, and viruses on hard surfaces. This easily applied, broad-spectrum disinfectant spray provides spray on cleaning and disinfection for hard surfaces, offering demonstrated efficacy against the SARS-CoV-2 virus that causes COVID-19. AEGIS VES 240 removes surface grease, grime and impurities, with a simultaneous disinfectant action, as well as working as a deodorizer to help remove musty and unpleasant odors on everything from bedding to walls and floors. AEGIS VES 240 has been evaluated according to the AOAC Germicidal Spray Products as Disinfectants test for determination of the efficacy of liquid disinfectants on hard, nonporous surfaces, and the ASTM Standard Test Method for Efficacy of Sanitizers Recommended for Inanimate, Hard, Nonporous Non-Food Contact Surfaces. For long-term protection, this product may be used to disinfect surfaces before the application of AEGIS antimicrobial surface protection technologies, such as our AEGIS Microbe Shield ®, completing the AEGIS Clean – Disinfect – Protect™ System of Care to provide durable surface protection from microbial degradation for up to 90 days. For more information, visit https://www.microban.com/aegis/aegis-disinfectant/aegis-ves-240 About AEGIS Environmental Management Inc. AEGIS Environmental Management Inc., headquartered in North Carolina with operations in North America, Europe and Asia Pacific, has been the sole source for AEGIS ® surface protection technologies since 1976. The company’s AEGIS System of Care consists of both disinfectants and antimicrobial surface coatings. Our disinfectants kill viruses and other germs on hard surfaces. Our antimicrobial coatings offer an effective way to control a wide range of microbes, including bacteria, fungi, algae, mold, and mildew, on surfaces found in healthcare, educational and public transportation settings. These technologies are incorporated into a three-step Clean-Disinfect-Protect approach to cleaner surfaces, developed to meet customer demand during the COVID-19 pandemic and into the future. The AEGIS portfolio incorporates a range of products with a unique mode of action, including AEGIS Microbe Shield, which are easy to apply on surfaces either by spraying or using the ‘wet and wipe’ method. The AEGIS and AEGIS Microbe Shield brands are recognized worldwide, trusted to solve most surface hygiene concerns, and suitable for use in a wide range of surfaces and environments. Often imitated but never replicated, AEGIS surface coatings offer continuous microbial surface protection that is durable and lasts 24/7. AEGIS Microbe Shield is the original EPA-registered antimicrobial surface coating. Complementing this is AEGIS VES 240, an EPA-registered hospital type disinfectant solution to address surface hygiene concerns in a wide array of environments. This one-step disinfectant is effective against pathogenic bacteria, fungi, animal and human viruses, with demonstrated efficacy against the SARS-CoV-2 virus that causes COVID-19, and sanitizes surfaces to kill 99.9 % of bacteria in 15 seconds on hard surfaces. Aegis Environmental Management Inc. is the lawful owner of the AEGIS, AEGIS VES 240, AEGIS System of Care, AEGIS Clean – Disinfect – Protect, and AEGIS Microbe Shield trademarks. For more information, visit www.aegismicrobeshield.com Contact Details kdm communications limited Sarah Khan +44 1480 405333 ideas@kdm-communications.com

May 25, 2021 10:43 AM Eastern Daylight Time

Image

1 ... 271 272 273 274 275 ... 305